Labgenius is a biotechnology company that uses artificial intelligence and robotics to accelerate the discovery and development of new protein therapeutics.
Labgenius was founded in 2012.
The company is based in London, United Kingdom.
Labgenius was founded by Dr. James Field.
Labgenius raised $3.66 million in a seed funding round in 2015.
In 2019, Labgenius secured $10 million in a series A funding round to support its expansion and further development of its AI-driven protein discovery platform.
Synthace is a global biotechnology company that develops software to automate and optimize biological discovery and development processes.
DeepMind is a subsidiary of Alphabet Inc. that specializes in artificial intelligence research and its applications.
AbCellera is a biotech company that leverages artificial intelligence to discover and develop monoclonal antibodies for therapeutic applications.
EvoT4 is Labgenius' flagship AI-driven protein discovery platform. It combines machine learning algorithms and laboratory automation to accelerate the identification and optimization of protein therapeutics.
Optimus is Labgenius' robotic platform that enables high-throughput protein engineering and production. It integrates robotics, liquid handling, and data analytics to streamline the protein development process.
Labgenius develops novel protein therapeutics for various disease targets. These therapeutics have the potential to revolutionize the treatment of conditions such as cancer, autoimmune disorders, and infectious diseases.
Labgenius is a biotechnology company that uses AI and robotics to accelerate the discovery and development of protein therapeutics.
Labgenius was founded in 2012.
Labgenius is based in London, United Kingdom.
Labgenius has developed the EvoT4 protein discovery platform, the Optimus robotic platform, and a range of protein therapeutics.
Some of Labgenius' competitors include Synthace, DeepMind, and AbCellera.
